Literature DB >> 9352605

Measurement of transcription factor c-fos and EGR-1 mRNA transcription levels in synovial tissue by quantitative RT-PCR.

B Grimbacher1, W K Aicher, H H Peter, H Eibel.   

Abstract

The transcription factors Fos and EGR-1 are known to be involved in the regulation of the transcription of metalloproteinases and their specific inhibitors. Since the overexpression of metalloproteinases is responsible for the matrix degradation in rheumatoid arthritis (RA), exact analysis of transcription levels of c-fos and EGR-1 ex vivo may serve to monitor progression or remission of the disease activity in RA. Here we report on a method based on a quantitative reverse transcription polymerase chain reaction (RT-PCR) for rapid estimation of the transcription levels of the immediate early genes c-fos and EGR-1. Coamplification with suitable internal standards, easily generated by the use of hybrid primers, allows us to semiquantitatively measure c-fos and EGR-1 induction levels in low numbers of cultured cells or very small tissue samples obtained by synovial biopsy. The sensitivity of the method was 3.5 pg/ml for c-fos- and 10 pg/ml for EGR-1-specific cDNAs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352605     DOI: 10.1007/s002960050018

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  3 in total

Review 1.  Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis.

Authors:  T Pap; U Müller-Ladner; R E Gay; S Gay
Journal:  Arthritis Res       Date:  2000-06-08

2.  Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes.

Authors:  Corinne Granet; Wova Maslinski; Pierre Miossec
Journal:  Arthritis Res Ther       Date:  2004-02-26       Impact factor: 5.156

3.  Transcriptional signature associated with early rheumatoid arthritis and healthy individuals at high risk to develop the disease.

Authors:  N Macías-Segura; J E Castañeda-Delgado; Y Bastian; D Santiago-Algarra; J D Castillo-Ortiz; A L Alemán-Navarro; E Jaime-Sánchez; M Gomez-Moreno; C A Saucedo-Toral; Edgar E Lara-Ramírez; M Zapata-Zuñiga; L Enciso-Moreno; R González-Amaro; C Ramos-Remus; J A Enciso-Moreno
Journal:  PLoS One       Date:  2018-03-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.